“We are committed to delivering innovative technologies and end-to-end solutions that address our customer’s biggest challenge in breast cancer detection, which is to help clinicians provide efficient, accurate and personalized diagnosis to patients,” says Pooja Pathak, Vice President and General Manager of Mammography at GE HealthCare. “With Pristina Via and SmartMammo, we have streamlined both exam and radiology workflows in breast cancer screening and diagnostics, enabling clinicians to prioritize patient care.”
Latest advancements for breast cancer detection:
Ad Statistics
Times Displayed: 19340
Times Visited: 365 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
Invenia™ Automated Breast Ultrasound (ABUS) Premium, the first FDA-approved breast ultrasound indicated as an adjunct to mammography and specifically designed for detecting cancer in dense breasts, will also be showcased at the Symposium. According to studies across the U.S. and Europe, 40% of women and 70% of Asian women have dense breast tissue.[7],[8] For patients with dense breasts, the addition of ABUS screening when used with mammography has demonstrated a 35.7% increase in cancer detection compared to mammography alone.[9] The latest Invenia ABUS Premium aims to deliver optimal outcomes with its innovative, patient-friendly, and efficient AI-driven technology. It features new integrated Verisound™ AI and AI Assistant [10], ensuring faster[11] and reproducible scanning and reading with extraordinary image quality. This increases clinical confidence, addresses workflow productivity, and aids in the detection of breast cancer in women with dense breasts.
SenoBright™ HD Contrast Enhanced Mammography (CEM) is a next-level mammogram that helps reduce the masking effect of fibroglandular breast tissue and increases the tumor signal to increase diagnostic confidence. It allows for imaging exams to be conducted in less than seven minutes and enables the detection of lesions that would otherwise go undetected,[12] providing patients with answers right away to help them avoid the anxiety of an inconclusive exam.
Serena Bright™ is a contrast guided biopsy system that enables providers to see lesions using CEM and sample with certainty. This allows patients to undergo breast biopsy exams using the same mammography equipment, in a familiar setting, with familiar staff, to help relieve some of the stress of a biopsy procedure.
To learn more about the personalized breast cancer screening solutions GE HealthCare will be featuring at SBI 2025, please visit booth #407.
Back to HCB News
